Stock AQST AQUESTIVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Aquestive Therapeutics, Inc. Stock

Equities

AQST

US03843E1047

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
4.07 USD +3.56% Intraday chart for Aquestive Therapeutics, Inc. -0.85% +101.49%
Apr. 12 Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology CI
Apr. 11 Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target MT

Financials (USD)

Sales 2024 * 50.21M Sales 2025 * 57.98M Capitalization 368M
Net income 2024 * -27M Net income 2025 * -27M EV / Sales 2024 * 6.93 x
Net cash position 2024 * 20.23M Net Debt 2025 * 15.47M EV / Sales 2025 * 6.62 x
P/E ratio 2024 *
-11.4 x
P/E ratio 2025 *
-13.8 x
Employees 135
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95%
More Fundamentals * Assessed data

Chart Aquestive Therapeutics, Inc.

Dynamic Chart

Latest news about Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology CI
Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target MT
Aquestive Therapeutics Files $250 Million Mixed Shelf MT
Aquestive Therapeutics, Inc. Appoints Abigail Jenkins to Board of Directors, Effective April 1, 2024 CI
Raymond James Initiates Aquestive Therapeutics With Outperform Rating, $7 Price Target MT
Top Midday Decliners MT
Sector Update: Health Care Stocks Steady Premarket Wednesday MT
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply MT
Top Premarket Decliners MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering; Shares Slump Premarket MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering MT
Aquestive Therapeutics Proposes Public Stock Offering -- Shares Drop MT
H.C. Wainwright Raises Price Target on Aquestive Therapeutics to $9 From $7, Maintains Buy Rating MT
JMP Securities Adjusts Price Target on Aquestive Therapeutics to $10 From $8, Maintains Market Outperform Rating MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday MT
More news

Latest transcript on Aquestive Therapeutics, Inc.

Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc., Q4 2023 Earnings Call, Mar 06, 2024
More transcripts

Analyst Recommendations on Aquestive Therapeutics, Inc.

Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target MT
Raymond James Initiates Aquestive Therapeutics With Outperform Rating, $7 Price Target MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering MT
H.C. Wainwright Raises Price Target on Aquestive Therapeutics to $9 From $7, Maintains Buy Rating MT
JMP Securities Adjusts Price Target on Aquestive Therapeutics to $10 From $8, Maintains Market Outperform Rating MT
More recommendations

Press releases Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET GL
Aquestive Therapeutics to Present Crossover Study Data for Libervant Buccal Film at 76th Annual Meeting of the American Academy of Neurology AQ
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology GL
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive GL
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive AQ
More press releases

News in other languages on Aquestive Therapeutics, Inc.

Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
More news

Quotes and Performance

1 day+3.56%
1 week-0.85%
Current month-4.46%
1 month-0.73%
3 months+70.29%
6 months+186.62%
Current year+101.49%
More quotes

Highs and lows

1 week
3.78
Extreme 3.775
4.50
1 month
3.72
Extreme 3.72
4.54
Current year
1.95
Extreme 1.95
6.23
1 year
1.25
Extreme 1.2514
6.23
3 years
0.62
Extreme 0.618
6.40
5 years
0.62
Extreme 0.618
10.00
10 years
0.62
Extreme 0.618
20.70
More quotes

Managers and Directors - Aquestive Therapeutics, Inc.

Managers TitleAgeSince
Daniel Barber CEO
 Chief Executive Officer 48 07-06-30
A. Toth DFI
 Director of Finance/CFO 65 20-12-30
Stephen Wargacki CTO
 Chief Tech/Sci/R&D Officer 46 14-12-31
Members of the board TitleAgeSince
Timothy Morris BRD
 Director/Board Member 61 22-08-09
Santo Costa CHM
 Chairman 78 15-11-30
Gregory Brown BRD
 Director/Board Member 70 07-02-28
More insiders

Quotes

Date Price Change Volume
24-04-26 4.07 +3.56% 2,986,647
24-04-25 3.93 +0.77% 1,935,903
24-04-24 3.9 -8.88% 2,147,676
24-04-23 4.28 -2.28% 1,699,537
24-04-22 4.38 +6.70% 1,825,960

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT

More quotes

Company Profile

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.
Sector
Pharmaceuticals
Calendar
2024-05-06 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Aquestive Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.07 USD
Average target price
9 USD
Spread / Average Target
+121.13%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
AQUESTIVE THERAPEUTICS, INC. Stock Aquestive Therapeutics, Inc.
+101.49% 368M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AQST Stock